Revolution Medicines, Inc.
RVMD
$149.94
$4.222.90%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 920.55M | 782.32M | 675.48M | 564.72M | 558.37M |
| Gross Profit | -920.55M | -782.32M | -675.48M | -564.72M | -558.37M |
| SG&A Expenses | 261.28M | 195.04M | 156.57M | 127.77M | 108.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.39B | 1.18B | 1.04B | 897.50M | 789.43M |
| Operating Income | -1.39B | -1.18B | -1.04B | -897.50M | -789.43M |
| Income Before Tax | -1.37B | -1.13B | -961.73M | -812.81M | -698.26M |
| Income Tax Expenses | -- | -- | -753.00K | -753.00K | -753.00K |
| Earnings from Continuing Operations | -1.37K | -1.13K | -960.98 | -812.06 | -697.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.37B | -1.13B | -960.98M | -812.06M | -697.51M |
| EBIT | -1.39B | -1.18B | -1.04B | -897.50M | -789.43M |
| EBITDA | -1.38B | -1.17B | -1.03B | -890.70M | -782.75M |
| EPS Basic | -7.07 | -5.92 | -5.18 | -4.50 | -4.00 |
| Normalized Basic EPS | -4.42 | -3.70 | -3.24 | -2.82 | -2.50 |
| EPS Diluted | -7.07 | -5.92 | -5.18 | -4.50 | -4.00 |
| Normalized Diluted EPS | -4.42 | -3.70 | -3.24 | -2.82 | -2.50 |
| Average Basic Shares Outstanding | 772.58M | 762.63M | 739.72M | 717.33M | 693.89M |
| Average Diluted Shares Outstanding | 772.58M | 762.63M | 739.72M | 717.33M | 693.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |